Adil Daud
University of California, San Francisco · UCSF Medical Center at Mount Zion · Cutaneous Oncology Group at the Helen Dillar Family Comprehensive Cancer Center at UCSF
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Adil Daud as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 20:31 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT05695898 · XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior Immune Checkpoint Inhibitor TherapyUniversity of California, San Francisco · terminated · Metastatic Melanoma, Advanced Melanoma · principal investigator
- N/ANCT05105100 · Peripheral T Cell Determinants of Response and Resistance to Pembrolizumab in MelanomaUniversity of California, San Francisco · completed · Melanoma, Advanced Melanoma · principal investigator
- Ph2NCT03396952 · Prostaglandin Inhibition and Immune Checkpoint Blockade in MelanomaUniversity of California, San Francisco · completed · Stage III Cutaneous Melanoma, Stage IIIA Cutaneous Melanoma, Stage IIIB Cutaneous Melanoma · principal investigator
- Ph2NCT02587650 · Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV MelanomaUniversity of California, San Francisco · terminated · ALK Fusion Protein Expression, BRAF wt Allele, Invasive Skin Melanoma · principal investigator
- Ph2NCT01941927 · Trametinib With GSK2141795 in BRAF Wild-type MelanomaAdil Daud · completed · Melanoma · principal investigator
- Ph1NCT01841463 · Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF MutationPiramal Enterprises Limited · suspended · Advanced or Inoperable Malignant Melanoma With BRAF Mutation · principal investigator
- Ph2NCT01174238 · A Two Arm Trial of Axitinib and Carboplatin/Paclitaxel in MelanomaAdil Daud · completed · Melanoma · principal investigator
- Ph1/Ph2NCT00597038 · A Phase I/II Study of Dasatinib and DacarbazineH. Lee Moffitt Cancer Center and Research Institute · completed · Metastatic Melanoma · study chair
- Ph1/Ph2NCT00496223 · A Phase I/II Study of Sunitinib and DacarbazineH. Lee Moffitt Cancer Center and Research Institute · terminated · Melanoma · principal investigator
- Ph1/Ph2NCT00358319 · Phase I/II Trial of Valproic Acid and Karenitecin for MelanomaH. Lee Moffitt Cancer Center and Research Institute · terminated · Malignant Melanoma · principal investigator
- N/ANCT00323206 · Phase I Trial of Intratumoral pIL-12 Electroporation in Malignant MelanomaH. Lee Moffitt Cancer Center and Research Institute · completed · Malignant Melanoma · principal investigator
- Ph1NCT00246103 · Phase I Trial of Valproic Acid and Epirubicin in Solid Tumor MalignanciesH. Lee Moffitt Cancer Center and Research Institute · completed · Neoplasms, Advanced · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 20:31 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 20:31 UTC. The ranking covers the 200 most relevant of 81 PubMed records, and a shared surname and initials can bring in a namesake. All 81 on PubMed
- Pembrolizumab versus Ipilimumab in Advanced Melanoma.N Engl J Med · 20154,791 citationsRCR 149.2
- Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.N Engl J Med · 20132,803 citationsRCR 76.7
- Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.N Engl J Med · 20122,244 citationsRCR 58.2
- 1,500 citationsRCR 40.5
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.Lancet Oncol · 20151,309 citationsRCR 40.1
- PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.N Engl J Med · 20161,007 citationsRCR 30.3
- 984 citationsRCR 29.7
- Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.Lancet Oncol · 2019952 citationsRCR 33.1
- Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.JAMA · 2016879 citationsRCR 25.8
- Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.Ann Oncol · 2019771 citationsRCR 27.0